Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Oct-Dec;4(4):313-318.
doi: 10.4103/apjon.apjon_40_17.

Importance of Glycemic Control in Cancer Patients with Diabetes: Treatment through End of Life

Affiliations
Review

Importance of Glycemic Control in Cancer Patients with Diabetes: Treatment through End of Life

Denise Soltow Hershey. Asia Pac J Oncol Nurs. 2017 Oct-Dec.

Abstract

Cancer patients with diabetes are at increased risk for developing infections, being hospitalized, and requiring chemotherapy reductions or stoppages. While it has been hypothesized that glycemic control increases the risk for these adverse events, few studies have explored this hypothesis. The purpose of this paper is to discuss the importance of glycemic control in patients with diabetes and cancer during treatment through end of life. Glycemic control was found to play a role; the overall level of health-related quality of life experienced by patients with cancer and diabetes, level of symptom severity experienced and can impact the overall survival of the individual. Evidence-based policies and practice guidelines also need to be developed to help clinicians manage these patients during all phases of care. Using diabetes educators and advance practice, nurses to provide management and care coordination services need to be considered. Survivorship care plans should address both cancer and diabetes management. Finally, glycemic control should continue through end of life, with the main goal of avoiding hypoglycemic events.

Keywords: Cancer; chemotherapy; diabetes; end of life; glycemic control; survivorship.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Similar articles

Cited by

References

    1. World Health Organization. Secondary World Health Organization. 2017. [Last accessed on 2017 Apr 06]. Available from: http://www.who.int/mediacentre/en/
    1. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, et al. Diabetes and cancer: A consensus report. Diabetes Care. 2010;33:1674–85. - PMC - PubMed
    1. Barone BB, Yeh HC, Snyder CF, Peairs KS, Stein KB, Derr RL, et al. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: A systematic review and meta-analysis. JAMA. 2008;300:2754–64. - PMC - PubMed
    1. Barone BB, Yeh HC, Snyder CF, Peairs KS, Stein KB, Derr RL, et al. Postoperative mortality in cancer patients with preexisting diabetes: Systematic review and meta-analysis. Diabetes Care. 2010;33:931–9. - PMC - PubMed
    1. Chia VM, O’Malley CD, Danese MD, Lindquist KJ, Gleeson ML, Kelsh MA, et al. Prevalence and incidence of comorbidities in elderly women with ovarian cancer. Gynecol Oncol. 2013;129:346–52. - PubMed